UK Markets close in 6 hrs 38 mins

(QCOR)

NasdaqGS . Currency in USD
Add to watchlist
Full screen
Previous closeN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's rangeN/A - N/A
52-week rangeundefined - undefined
VolumeN/A
Avg. volumeN/A
Market capN/A
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • American City Business Journals6 months ago

    Mallinckrodt to pay $100 million in settlement with FTC

    Mallinckrodt has agreed to pay $100 million to settle Federal Trade Commission charges that it violated antitrust laws in relation to the market for Acthar, the company’s top-selling drug. The FTC alleges that Mallinckrodt and its Mallinckrodt ARD Inc. division, formerly known as Questcor Pharmaceuticals Inc., violated the laws when Questcor acquired “the rights to a drug that threatened its monopoly in the U.S. market” for adrenocortocotropic hormone drugs (ACTH) such as Acthar. Acthar is a specialty drug used to treat infantile spasms and other serious medical conditions.

  • Reuters6 months ago

    Mallinckrodt to pay $100 mln to settle U.S. probe on drug pricing

    Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the Federal Trade Commission said on Wednesday. Mallinckrodt's share price dropped sharply to just under $43 from above $49 on a report Wednesday, which proved incorrect, that the FTC would sue Mallinckrodt. In 2001, Questcor bought the rights to Acthar, a type of hormone-based drug used to treat infantile spasms as well as multiple sclerosis.

  • TheStreet.com6 months ago

    Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

    Regulators say company squelched competing drug for infant seizures.

By using Yahoo, you agree that Yahoo and its partners may use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more